Adaptive Biotechnologies' Lo sells 18,698 shares
The transactions were made under a Rule 10b5-1 trading plan adopted September 15, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised three stock-option tranches on October 1, 2026, for 8,038 shares at an $8.46 exercise price, 9,377 shares at $3.99, and 9,377 shares at $8.12; corresponding common-stock acquisitions were reported. On the same date, Lo sold 8,094 shares at a weighted-average price of $27.52 and 18,698 shares at a weighted-average price of $28.61. Both sale prices were weighted averages within ranges stated in the transaction footnotes. The transactions were made under a Rule 10b5-1 trading plan adopted September 15, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 26,792 shares ($576K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
LO FRANCIS
Role
Chief People Officer
Sold
26,792 shs ($758K)
Approx. gross sale proceeds
$758K
Approx. exercise cost
$182K
Approx. pre-tax spread
$576K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F4 | 8,038 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F5 | 9,377 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1, F6 | 9,377 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,038 | $8.46 | $68K |
| Exercise | Common Stock F1 | 9,377 | $3.99 | $37K |
| Exercise | Common Stock F1 | 9,377 | $8.12 | $76K |
| Sale | Common Stock F1, F2 | 8,094 | $27.52 | $223K |
| Sale | Common Stock F1, F3 | 18,698 | $28.61 | $535K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 166,099 contracts (Direct);
Common Stock — 220,867 shares (Direct);
Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (6)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Option exercise tranche: 8,038 shares at an $8.46 exercise price
Option exercise tranche: 9,377 shares at a $3.99 exercise price
Option exercise tranche: 9,377 shares at an $8.12 exercise price
+3 more
6 metrics
Option exercise tranche
8,038 shares at an $8.46 exercise price
October 1, 2026
Option exercise tranche
9,377 shares at a $3.99 exercise price
October 1, 2026
Option exercise tranche
9,377 shares at an $8.12 exercise price
October 1, 2026
Shares sold
8,094 shares at a weighted-average price of $27.52 per share
October 1, 2026; sale prices ranged from $27.22 to $28.22
Shares sold
18,698 shares at a weighted-average price of $28.61 per share
October 1, 2026; sale prices ranged from $28.33 to $29.00
Indirect Common Stock holding
2,500 shares
Held by spouse You Jin Lee
Key Terms
Rule 10b5-1 trading plan, weighted average price, vesting, continuous service
4 terms
Rule 10b5-1 trading plan regulatory
"Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting technical
"1/48 of such shares vesting thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service technical
"at the end of each full month of continuous service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were Francis Lo's ADPT transactions made under a Rule 10b5-1 plan?
Yes. The transactions were made under a Rule 10b5-1 trading plan adopted September 15, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
